The human clinical trial about improvement effect of MaquiBright supplementation on dry eye and eye fatigue symptoms
- Conditions
- healthy subject
- Registration Number
- JPRN-UMIN000019374
- Lead Sponsor
- Tsubota-lab
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 105
Not provided
1.Subjects diagnosed with definite dry eye by Diagnosis Criteria of Dry Eye 2.Subjects wearing contact lenses. 3.Subjects consuming dietary supplement(s) or over the counter drug(s) included eye drops within participation one month. 4.Subjects are likely to change the number of times using artificial tears a day. 5.Subjects using artificial tears more than seven times a day. 6.Subjects who are using dry eye treatment drugs (However,it is selectable that the subjects have passed two weeks after discontinuation using a dry eye treatment drug, and do not use the drug during this study.) 7.Subjects who are currently suffering any ophthalmic disease (including conjunctival laxity),or anamnesis with serious eye disease 8.Subjects who are using eye drops for other ophthalmic diseases 9.Subjects diagnosed with Sjogren's syndrome 10.Subjects at risk of developing hay fever during October to january 11.Subjects with chronic disease of asthma 12.Subjects in medication, or who have anamnesis with serious eye disease that require medication 13.Subjects who underwent eye surgery during the past 3 months 14.Subjects who are allergic to the test sample 15.Subjects who had participated in other clinical trial within one month prior to the participation agreement of this study,or who are planning to participate in other clinical trials after the participation agreement of this study 16.Subjects who are planning pregnancy or breast-feeding during the study period 17.Others,subjects who are determined to be inappropriate as a subject by the doctor or researcher responsible for the trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method tear film break-up time (BUT examination), strip meniscometry, Schirmer 1 test, subjective symptoms questionnaire (DEQS, VAS);investigation at start, 4 weeks treatment and after 8 weeks treatment
- Secondary Outcome Measures
Name Time Method corneal and conjunctival epithelial disorder score, meibomian glands (MG) evaluation, continuous near-point measurement and flicker vision, visual acuity